New study tests everolimus for kidney tumors in TSC patients
NCT ID NCT05252585
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how safe and effective the drug everolimus is for Taiwanese adults with tuberous sclerosis complex (TSC) who have kidney tumors called angiomyolipomas. Four participants will take the drug and be monitored for side effects and tumor shrinkage. The goal is to control the disease, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL ANGIOMYOLIPOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Taichung, Taiwan ROC, 40201, Taiwan
-
Novartis Investigative Site
Taoyuan, Taiwan ROC, 33305, Taiwan
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Novartis Investigative Site
Taoyuan, 33305, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain imaging may unlock early clues to autism in tuberous sclerosis
- Play therapy may boost social skills in infants with tuberous sclerosis — a trial puts it to the test
- New daily pill aims to tame stubborn seizures in tuberous sclerosis
- New italian model aims to ease epilepsy care transition for teens
- Massive TSC data and tissue bank opens to researchers
- Walking analysis sheds light on rare genetic disorders